Archives

Food noise, quieted cravings, grey-market retatrutide: what measured analyses of millions of posts show users report, and how it lines up with the trials.

Hearts, kidneys, livers, sleep apnoea, alcohol: how weight-loss trial results kept producing new findings, new licences and a wave of follow-on research.

One receptor, then two, then three. What the STEP, SURMOUNT and TRIUMPH programmes measured, how the three molecules compare, and where each stands with regulators.

Two GHRH analogues - one a former licensed medicine, one abandoned in phase 2 - and a ghrelin-receptor pentapeptide that failed its only clinical-endpoint trial. What each record actually contains.

Refrigerated at 4-8 C at all times, picked and packed on despatch day, and shipped in plain, sealed packaging. What happens to a vial between our stock and your post.

Every citation is resolved against its primary record before publication. The rule, the process - and what it caught in our own drafts, including a fabricated author list.

How open-banking payment works at our checkout, who regulates it, what it costs in protections against a card - honestly - and why cards are scarce across this whole category.

Convictions, an FDA raid, fifty warning letters and the closure of the biggest names: the US shake-out on the record, and what a UK buyer of an overseas site now faces.

What Border Force and the MHRA actually seize, the 3-month postal allowance that does not exist in official guidance, where research chemicals sit - and the parcel that never meets a border.

Where UK research demand actually sits in 2026: the six compounds every published list agrees on, what our own search data adds, and the prescription-class exception we document but do not sell.